We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 16, 2021

Pan-Cancer Prediction of Radiotherapy Benefit Using Genomic-Adjusted Radiation Dose

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Pan-Cancer Prediction of Radiotherapy Benefit Using Genomic-Adjusted Radiation Dose (GARD): A Cohort-Based Pooled Analysis
Lancet Oncol 2021 Aug 04;[EPub Ahead of Print], JG Scott, G Sedor, P Ellsworth, JA Scarborough, KA Ahmed, DE Oliver, SA Eschrich, MW Kattan, JF Torres-Roca

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading